卡络磺钠联合雷贝拉唑治疗溃疡性上消化道出血的临床研究  

Clinical Study of Sodium Carisoprodol Combined with Rabeprazole in the Treatment of Ulcerative Upper Gastrointestinal Bleeding

作　　者：雷曜 Yao Lei(Xingpu Hospital,Suzhou Industrial Park,Suzhou,Jiangsu 215025)

机构地区：[1]苏州工业园区星浦医院,江苏苏州215025

出　　处：《医学研究前沿》2025年第2期46-48,共3页Frontiers of Medical Research

摘　　要：目的目的探究临床溃疡性上消化道出血(U-UGIB)治疗中雷贝拉唑药物联合卡络磺钠药物的疗效。方法方法本文从2021年1月起筛选U-UGIB患者,并于2023年12月结束,共80例U-UGIB患者受试,按用药不同分为LH组(联合雷贝拉唑药物与卡络磺钠药物,40例)和DY组(单用雷贝拉唑药物,40例)。对比炎症水平变化、副反应、疗效结局及消除症状用时。结果结果两组出组时的炎症水平与入组时比较均降低,且LH组的炎症水平更低(P<0.05)。与DY组比较,LH组的副反应更少,疗效更高,消除症状用时更优(P<0.05)。结论结论临床U-UGIB治疗中雷贝拉唑药物联合卡络磺钠药物可获得更优疗效,既能对炎症予以缓解,也可对各症状予以快速消除,且副反应更少,疗效更为可靠,安全性更高,可借鉴研究。Objective To investigate the efficacy of rabeprazole combined with sodium cargosulfate in the treatment of clinical ulcerative upper gastrointestinal bleeding(U-UGIB).Method In this paper,U-UGIB patients were screened from January 2021 and finished in December 2023,a total of 80 U-UGIB patients were subjected to the test,which were divided into LH group(combined rabeprazole drug and cargosulfan sodium drug,40 cases)and DY group(rabeprazole drug alone,40 cases)according to the different drugs used.Changes in inflammation levels,side effects,efficacy outcomes and time taken to eliminate symptoms were compared.Result Inflammation levels were lower in both groups at the time of exit compared with the time of entry,and were lower in the LH group(P<0.05).Compared with the DY group,the LH group had fewer side effects,higher efficacy,and better symptom elimination time(P<0.05).Conclusion The combination of rabeprazole and sodium carisoprodol in clinical U-UGIB treatment can achieve better efficacy,which can not only alleviate the inflamma⁃tion,but also eliminate the symptoms quickly,with fewer side effects,more reliable efficacy and higher safety,which can be studied.

关 键 词：溃疡性上消化道出血 雷贝拉唑 卡络磺钠 炎症水平 副反应 

分 类 号：R573.2[医药卫生—消化系统]